Middle East Pharmaceutical Industries Balance Sheet Health
Financial Health criteria checks 5/6
Middle East Pharmaceutical Industries has a total shareholder equity of SAR326.2M and total debt of SAR73.6M, which brings its debt-to-equity ratio to 22.6%. Its total assets and total liabilities are SAR494.0M and SAR167.8M respectively. Middle East Pharmaceutical Industries's EBIT is SAR91.4M making its interest coverage ratio 19.7. It has cash and short-term investments of SAR13.8M.
Key information
22.6%
Debt to equity ratio
ر.س73.58m
Debt
| Interest coverage ratio | 19.7x |
| Cash | ر.س13.80m |
| Equity | ر.س326.19m |
| Total liabilities | ر.س167.85m |
| Total assets | ر.س494.04m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4016's short term assets (SAR323.8M) exceed its short term liabilities (SAR145.0M).
Long Term Liabilities: 4016's short term assets (SAR323.8M) exceed its long term liabilities (SAR22.8M).
Debt to Equity History and Analysis
Debt Level: 4016's net debt to equity ratio (18.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 4016's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 4016's debt is well covered by operating cash flow (83.6%).
Interest Coverage: 4016's interest payments on its debt are well covered by EBIT (19.7x coverage).